AU2018284330B2 - Treatment for migraine - Google Patents

Treatment for migraine Download PDF

Info

Publication number
AU2018284330B2
AU2018284330B2 AU2018284330A AU2018284330A AU2018284330B2 AU 2018284330 B2 AU2018284330 B2 AU 2018284330B2 AU 2018284330 A AU2018284330 A AU 2018284330A AU 2018284330 A AU2018284330 A AU 2018284330A AU 2018284330 B2 AU2018284330 B2 AU 2018284330B2
Authority
AU
Australia
Prior art keywords
leucine
acetyl
migraine
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018284330A
Other languages
English (en)
Other versions
AU2018284330A1 (en
Inventor
Mallory Factor
Michael Strupp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intrabio Ltd
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59358204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018284330(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of AU2018284330A1 publication Critical patent/AU2018284330A1/en
Application granted granted Critical
Publication of AU2018284330B2 publication Critical patent/AU2018284330B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018284330A 2017-06-14 2018-06-25 Treatment for migraine Active AU2018284330B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine
GB1709459.0 2017-06-14
PCT/IB2018/054676 WO2018229738A1 (en) 2017-06-14 2018-06-25 Treatment for migraine

Publications (2)

Publication Number Publication Date
AU2018284330A1 AU2018284330A1 (en) 2020-01-02
AU2018284330B2 true AU2018284330B2 (en) 2024-03-14

Family

ID=59358204

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018284330A Active AU2018284330B2 (en) 2017-06-14 2018-06-25 Treatment for migraine

Country Status (25)

Country Link
US (1) US11471434B2 (cg-RX-API-DMAC10.html)
EP (1) EP3638370B1 (cg-RX-API-DMAC10.html)
JP (1) JP7130739B2 (cg-RX-API-DMAC10.html)
KR (1) KR102594130B1 (cg-RX-API-DMAC10.html)
CN (1) CN111093772B (cg-RX-API-DMAC10.html)
AU (1) AU2018284330B2 (cg-RX-API-DMAC10.html)
CY (1) CY1123860T1 (cg-RX-API-DMAC10.html)
DK (1) DK3638370T3 (cg-RX-API-DMAC10.html)
ES (1) ES2847169T3 (cg-RX-API-DMAC10.html)
GB (1) GB201709459D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20210108T1 (cg-RX-API-DMAC10.html)
HU (1) HUE053089T2 (cg-RX-API-DMAC10.html)
IL (1) IL271211B2 (cg-RX-API-DMAC10.html)
LT (1) LT3638370T (cg-RX-API-DMAC10.html)
MA (1) MA49396B1 (cg-RX-API-DMAC10.html)
MD (1) MD3638370T2 (cg-RX-API-DMAC10.html)
MX (1) MX387909B (cg-RX-API-DMAC10.html)
PL (1) PL3638370T3 (cg-RX-API-DMAC10.html)
PT (1) PT3638370T (cg-RX-API-DMAC10.html)
RS (1) RS61481B1 (cg-RX-API-DMAC10.html)
SG (1) SG11201912146RA (cg-RX-API-DMAC10.html)
SI (1) SI3638370T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202100037T1 (cg-RX-API-DMAC10.html)
WO (1) WO2018229738A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201908087B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65663B1 (sr) 2018-02-15 2024-07-31 Intrabio Ltd Acetil leucin za upotrebu u lečenju sindroma nemirnih nogu
CN120157593A (zh) * 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008032222A2 (en) * 2006-09-13 2008-03-20 Pierre Fabre Medicament Treatment of vertigo with acetyl-l-leucine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701662L (sv) * 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
AR044688A1 (es) * 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
ES2322707T3 (es) * 2003-07-03 2009-06-25 Euro-Celtique S.A. Derivados de 2-piridina alquino utiles para tratar el dolor.
ES2327684T3 (es) * 2003-07-24 2009-11-02 Euro-Celtique S.A. Compuestos heteroaril-tetrahidropiridilo utiles para el tratamiento o la prevencion del dolor.
SI1664041T1 (sl) * 2003-09-22 2008-12-31 Euro Celtique Sa Fenil-karboksamidne spojine, uporabne za tretiranje bolečine
MXPA06003123A (es) * 2003-09-22 2006-05-31 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor.
ES2322907T3 (es) * 2003-12-30 2009-07-01 Euro-Celtique S.A. Piperazinas utiles para el tratamiento de dolor.
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
US8921373B2 (en) * 2010-06-22 2014-12-30 Shionogi & Co., Ltd. Compounds having TRPV1 antagonistic activity and uses thereof
CA2803166C (en) 2010-06-25 2023-03-07 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
MX376862B (es) 2010-11-09 2025-03-07 Mannkind Corp Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas.
US9394293B2 (en) * 2011-08-10 2016-07-19 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
PT3445351T (pt) 2016-04-19 2024-11-14 Intrabio Ltd Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade
TN2019000033A1 (fr) 2016-08-11 2020-07-15 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
PT3482754T (pt) 2016-08-11 2021-02-03 Intrabio Ltd Composições farmacêuticas e utilizações contra os distúrbios de armazenamento lisossómico
PT3600276T (pt) 2017-03-28 2023-07-11 Intrabio Ltd Beta-histina, ou um seu sal farmaceuticamente aceitável, e um inibidor da monoamina oxidase, para utilização no tratamento ou prevenção de um ou mais sintomas de vertigem num indivíduo
US11793782B2 (en) 2017-10-18 2023-10-24 Intrabio Limited Therapeutic agents for neurodegenerative diseases
EP3697406A1 (en) 2017-10-18 2020-08-26 IntraBio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
RS65663B1 (sr) 2018-02-15 2024-07-31 Intrabio Ltd Acetil leucin za upotrebu u lečenju sindroma nemirnih nogu
CN120157593A (zh) 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
CN119097618A (zh) 2019-03-02 2024-12-10 内在生物技术有限公司 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008032222A2 (en) * 2006-09-13 2008-03-20 Pierre Fabre Medicament Treatment of vertigo with acetyl-l-leucine

Also Published As

Publication number Publication date
KR102594130B1 (ko) 2023-10-24
AU2018284330A1 (en) 2020-01-02
CA3067321A1 (en) 2018-12-20
JP2020526575A (ja) 2020-08-31
ES2847169T3 (es) 2021-08-02
MD3638370T2 (ro) 2021-04-30
CN111093772B (zh) 2023-11-03
IL271211B2 (en) 2024-01-01
RU2020100475A3 (cg-RX-API-DMAC10.html) 2021-10-22
DK3638370T3 (da) 2021-01-25
HUE053089T2 (hu) 2021-06-28
SI3638370T1 (sl) 2021-04-30
WO2018229738A1 (en) 2018-12-20
ZA201908087B (en) 2024-11-27
BR112019026660A2 (pt) 2020-07-14
HRP20210108T1 (hr) 2021-03-19
SG11201912146RA (en) 2020-01-30
RS61481B1 (sr) 2021-03-31
RU2020100475A (ru) 2021-07-14
MA49396A (fr) 2020-04-22
CN111093772A (zh) 2020-05-01
EP3638370B1 (en) 2020-11-11
SMT202100037T1 (it) 2021-03-15
US20200253905A1 (en) 2020-08-13
LT3638370T (lt) 2021-03-25
KR20210013518A (ko) 2021-02-04
MA49396B1 (fr) 2021-03-31
MX2019014784A (es) 2021-11-16
IL271211A (en) 2020-01-30
EP3638370A1 (en) 2020-04-22
PT3638370T (pt) 2021-01-26
JP7130739B2 (ja) 2022-09-05
CY1123860T1 (el) 2022-05-27
IL271211B1 (en) 2023-09-01
PL3638370T3 (pl) 2021-05-17
US11471434B2 (en) 2022-10-18
GB201709459D0 (en) 2017-07-26
MX387909B (es) 2025-03-19

Similar Documents

Publication Publication Date Title
US11471434B2 (en) Treatment for migraine
KR102791288B1 (ko) 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
US20210353559A1 (en) Composition and method for treating neurological disease
KR102693607B1 (ko) 하지 불안 증후군을 치료하기 위한 치료제
US10500170B2 (en) Composition and method for treating neurological disease
US11833121B2 (en) Composition and method for treating neurological disease
CA3067321C (en) Use of acetyle-leucine to prevent and/or treat migraine
RU2772278C2 (ru) Лечение мигрени
HK40023292A (en) Treatment of migraine with acetyl-leucine
HK40023292B (en) Treatment of migraine with acetyl-leucine
KR20070083903A (ko) 경구 효과적인 칸나비노이드 유사체
BR112019026660B1 (pt) Uso de acetil-leucina ou seu sal para preparação demedicamento para tratar ou prevenir enxaqueca ou sintomas associados
US20140148465A1 (en) Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine
AU2012391533B2 (en) Combination for the prophylaxis and treatment of behavioural, mental and cognitive disorders
US20240293435A1 (en) Methods and Compositions for Treating Human Disorders Using D-Cycloserine and a Psychedelic Agent
JP2024505283A (ja) 遂行機能障害の処置のための併用療法